BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31558432)

  • 21. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
    Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
    Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
    Taylor J; Lee SC
    Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
    Jenkins JL; Kielkopf CL
    Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations.
    Flach J; Jann JC; Knaflic A; Riabov V; Streuer A; Altrock E; Xu Q; Schmitt N; Obländer J; Nowak V; Danner J; Mehralivand A; Hofmann F; Palme I; Jawhar A; Wuchter P; Metzgeroth G; Nolte F; Hofmann WK; Nowak D
    Haematologica; 2021 Nov; 106(11):2906-2917. PubMed ID: 33054116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
    Nagehan P; Sabbir M; Song J; Mohammad H
    J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
    Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
    Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
    Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
    Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
    Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
    Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [RNA splicing dysregulation in hematological malignancies].
    Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
    Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].
    Li L; Xiao ZJ; Sun XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):617-621. PubMed ID: 28446323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
    Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
    Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Splicing factor mutations in myelodysplastic syndromes].
    Shiozawa Y
    Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
    Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
    Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
    Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
    Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ineffective erythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.